13125 Berlin, de
+49 (30) 941084-138
Eckert & Ziegler: Sales Grow by 32%, Profits by 40%
The Group's traditional segments (Nuclear Medicine & Industry segment, Therapy segment) were responsible for around two thirds of the growth in sales, or around 1.6 million EUR, while the new Radiopharmaceutical segment accounted for the rest (1.1 million EUR). The Therapy segment, which acquired no new companies last year, showed an organic growth in sales of 16%. The Nuclear Medicine & Industry segment, for which results from the American company Analytics Inc. and the Czech company SORAD s.r.o. are being consolidated for the first time in a first quarter, posted a 20% increase.
The increase in profit over the same quarter of last year derives primarily from higher sales in the Group's traditional segments and a higher than expected contribution from the Radiopharmaceutical segment.
For the ongoing year, the Board of Directors anticipates sales of around 50 million EUR and a return to the profit level of the year before last (approx. 0.75 EUR per share).
Eckert & Ziegler is a globally active specialist for radiation applications in medicine, science and industry. Its main areas of activity are cancer therapy, nuclear medical diagnostics and measurement technology. Listed on the Frankfurt Prime Standard (ISIN DE0005659700), the Group is headquartered in Berlin-Buch and has approximately 280 employees. In addition to sites in Germany, it has subsidiaries in Los Angeles, Atlanta, Prague, Paris, Milan and Chennai (India).
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.